25
Participants
Start Date
February 28, 2011
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Atazanavir
Capsule, oral, 300 mg, once daily, 10 days
Atazanavir
Capsule, oral, 400 mg, once daily, 7 days
Ritonavir
Capsule, oral, 100 mg, once daily, 10 days
Ritonavir
Capsule, oral, 100 mg, once daily, 7 days
Tenofovir (TDF)
Capsule, oral, 300 mg, once daily, 10 days
Tenofovir (TDF)
Capsule, oral, 300 mg, once daily, 7 days
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Oral, 10 days
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Oral, 7 days
Famotidine (FAM)
Tablet, oral, 20 mg, twice daily, 7 days
Famotidine (FAM)
Tablet, oral, 40 mg, twice daily, 7 days
Local Institution, Berlin
Local Institution, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY